An Introduction to Atrial Fibrillation
In recent years the management of patients with atrial fibrillation (AF) has made good progress, however it still remains one of the major causes of stroke, heart failure, sudden death, and cardiovascular morbidity globally. Community awareness of arrhythmias and detection are important to allow early diagnosis and treatment to avoid stroke and other complications.
Browse the content below where leading experts discuss the latest data in video interviews and short articles from our conference hub, and browse the selection of peer- reviewed articles from our journal portfolio.
Our supporting partners do not constitute an endorsement of the content on this page.
Atrial Fibrillation Content
Globe Pulsed Field System for High-definition Mapping and Ablation for Atrial Fibrillation
Heart International. 2022;16(2):85–90 DOI: https://doi.org/10.17925/HI.2022.16.2.85
Catheter ablation has emerged as an effective strategy for the treatment of atrial fibrillation (AF), even becoming a first-line option for selected patients.1 Pulmonary vein isolation (PVI) is the cornerstone of this procedure. Ablation beyond PVI is often practised, but scientific evidence from randomized clinical trials is still controversial.2–8 Point-by-point radiofrequency (RF) ablation has been, by […]
Should Catheter Ablation for Atrial Fibrillation be a Priority in Patients with Heart Failure with Reduced Ejection Fraction?
European Journal of Arrhythmia & Electrophysiology. 2022;8(1):20-4 DOI: https://doi.org/10.17925/EJAE.2022.8.1.20
Heart failure (HF) and atrial fibrillation (AF) are inexorably linked. They frequently coexist and share common risk factors, including ageing, hypertension, diabetes, obesity, sleep apnoea and coronary disease.1–4 Over half of patients with HF develop AF at some point,5 and when AF occurs, it is associated with an increase in total mortality of up to 40%.6 In addition, […]
Foreword – European Journal of Arrhythmia & Electrophysiology, Volume 8, Issue 1, 2022
Welcome to the latest edition of European Journal of Arrhythmia & Electrophysiology. Cardiac arrhythmias, the most common of which is atrial fibrillation, represent a substantial health and economic burden worldwide. In the last two decades we have observed major breakthroughs in the management of arrhythmias, particularly in the field of cardiac electrophysiology, and some of the […]
Ole De Backer, TCT 2022: FEops HEARTguide™ Computational Modelling for left atrial appendage (LAA) closure, the PREDICT LAA trial
The PREDICT LAA trial aimed to examine whether cardiac computed tomography- based FEops HEARTguide™ computational modelling would benefit clinical outcomes when planning for left atrial appendage (LAA) closure. In this touchCARDIO interview, we speak with Dr Ole De Backer (Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark) to discuss the PREDICT LAA trial and the next steps. […]
Ole De Backer, TCT 2022: The use of cardiac computed tomography-based patient-specific computational simulations in left atrial appendage (LAA) closure
When performing percutaneous left atrial appendage (LAA) closure, challenges arise that impact clinical outcomes and cardiac computed tomography (CCT)- based patient-specific computational simulations provide device-host interactions. In this touchCARDIO interview, we speak with Dr Ole De Backer (Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark) to discuss these challenges and the use of cardiac computed tomography (CCT)- […]
Hugh Calkins: What can we look forward to at the Heart Rhythm Congress 2022
Prof Hugh Calkins (The Johns Hopkins University School of Medicine, Baltimore, Md, USA) explains how the Arrhythmia Alliance has been instrumental in empowering patients to become advocates for themselves, ask more questions and increase their knowledge. The Heart Rhythm Congress 2022 is back in person and a unique chance to bring patients and healthcare professionals […]
Renato Lopes, ESC 2022: Rivaroxaban for patients with atrial fibrillation and bioprosthetic mitral valves, the RIVER trial
The RIVER trial pre-specified analysis presented at ESC 2022 aimed to test the efficacy/safety of rivaroxaban compared to warfarin in patients with atrial fibrillation (AF) and bioprosthetic mitral valves, according to time of valve implantation. In this touchCARDIO interview, we speak with Professor Renato Lopes (Duke University Medical Center, Durham, NC, USA) to discuss non-vitamin […]
Wern Yew Ding, ESC 2022: The risk of adverse events despite anticoagulation in patients with atrial fibrillation, the GLORIA-AF registry (phase II/III results)
This post-hoc analysis, using data from the GLORIA-AF registry, aimed to evaluate the risk of adverse events, primarily the risk of ischaemic stroke, despite anticoagulation in patients with atrial fibrillation. Secondary outcomes were all-cause death, cardiovascular death and myocardial infarction. In this touchCARDIO interview, we speak with Dr Wern Yew Ding (Liverpool Heart and Chest […]
Ben Freedman: Why should HCPs register for Heart Rhythm Congress 2022?
Prof Ben Freedman (The Heart Research Institute, Newtown, Australia) shares his excitement for the forthcoming in-person Heart Rhythm Congress 2022. He provides a sneak peak into the exciting programme and the sessions he is involved in. Questions What are you looking forward to at the Heart Rhythm Congress 2022? (00:28-01:00) Please summarize the key take-home […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!